Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 222

1.

Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.

Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.

J Urol. 2006 May;175(5):1679-83; discussion 1683.

PMID:
16600728
2.

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

Kiratli BJ, Srinivas S, Perkash I, Terris MK.

Urology. 2001 Jan;57(1):127-32.

PMID:
11164157
3.

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.

Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.

Prostate Cancer Prostatic Dis. 2002;5(4):304-10.

4.

Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.

Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J.

BJU Int. 2009 Dec;104(11):1637-40. doi: 10.1111/j.1464-410X.2009.08622.x. Epub 2009 Jun 22.

5.
6.

Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.

Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT.

Urology. 2007 Jul;70(1):122-6.

PMID:
17656221
7.
8.

Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.

Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.

Urology. 2007 Mar;69(3):500-4.

PMID:
17382153
9.

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV.

J Urol. 2006 Sep;176(3):972-8; discussion 978.

PMID:
16890673
10.

Androgen deprivation therapy for prostate cancer results in significant loss of bone density.

Wei JT, Gross M, Jaffe CA, Gravlin K, Lahaie M, Faerber GJ, Cooney KA.

Urology. 1999 Oct;54(4):607-11.

PMID:
10510915
11.

Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy.

Wang W, Yuasa T, Tsuchiya N, Maita S, Kumazawa T, Inoue T, Saito M, Ma Z, Obara T, Tsuruta H, Satoh S, Habuchi T.

Endocr Relat Cancer. 2008 Dec;15(4):943-52. doi: 10.1677/ERC-08-0116. Epub 2008 Jul 30.

PMID:
18667685
12.

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N.

J Urol. 2003 Jun;169(6):2008-12.

PMID:
12771706
13.

Long-term effects of androgen deprivation therapy in prostate cancer patients.

Basaria S, Lieb J 2nd, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS.

Clin Endocrinol (Oxf). 2002 Jun;56(6):779-86.

PMID:
12072048
14.

Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.

Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S.

Cancer. 2009 Aug 1;115(15):3468-74. doi: 10.1002/cncr.24404.

15.

Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.

Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K.

Int J Urol. 2007 Dec;14(12):1071-5.

16.

Androgen deprivation in veterans with prostate cancer: implications for skeletal health.

Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME.

Ann Pharmacother. 2006 Dec;40(12):2107-14. Epub 2006 Nov 28.

PMID:
17132807
17.

Risk factors for bone loss with prostate cancer in Korean men not receiving androgen deprivation therapy.

Kim SO, Kang TW, Kwon D, Park K, Ryu SB.

Int Braz J Urol. 2009 Mar-Apr;35(2):183-8; discussion 189.

18.

Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.

Yuasa T, Maita S, Tsuchiya N, Ma Z, Narita S, Horikawa Y, Yamamoto S, Yonese J, Fukui I, Takahashi S, Hatake K, Habuchi T.

Urology. 2010 May;75(5):1131-7. doi: 10.1016/j.urology.2009.10.075. Epub 2010 Feb 16.

PMID:
20163839
19.

Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.

Galvão DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R.

BJU Int. 2008 Jul;102(1):44-7. doi: 10.1111/j.1464-410X.2008.07539.x. Epub 2008 Mar 11. Erratum in: BJU Int. 2008 Aug;102(3):418.

20.

Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.

Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R, Ehrlich L, Kiss A, Danjoux C.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1239-45. doi: 10.1016/j.ijrobp.2012.11.007. Epub 2012 Dec 19.

PMID:
23265571

Supplemental Content

Support Center